Advitech's Dermylex'TM' will be Marketed by PhotoMedex in Five U.S. Areas by the end of February 2006 and will be Presented at the American Academy of Dermatology Conference...QUEBEC -- Advitech Inc. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension VENTURE:AVI (Audio Video Interleaved) A Windows multimedia video format from Microsoft. It interleaves standard waveform audio and digital video frames (bitmaps) to provide reduced animation at 15 fps at 160x120x8 resolution. Audio is 11,025Hz, 8-bit samples. ) ... in San Francisco on March 2-6, 2006 - Dermylex(TM) will be presented to 10,000 dermatologists Advitech Inc. (TSX-V: AVI) today announced that PhotoMedex Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : PHMD), will pre-launch Dermylex(TM) in five U.S. areas (San Francisco, CA, Los Angeles, CA, Dallas, TX, New York, NY and Cleveland, OH) during the last week of February 2006. PhotoMedex will also introduce Dermylex(TM) at the American Academy of Dermatology The American Academy of Dermatology (AAD) is the largest organization of dermatologists in the world. The Academy grants Fellowships and Associate Memberships, as well as Fellowships for Nonresidents (of the United States of America or Canada). (AAD AAD American Academy of Dermatology. AAD American Association of Dermatology ) Conference, the largest dermatology convention in the United States. The Conference will take place in San Francisco from March 2 to March 6 when more than 10,000 dermatologists from around the world will be welcomed. Commenting on the news, Renaud Beauchesne, Chief Executive Officer of Advitech said: "We are very pleased with the plan that PhotoMedex has put together for the introduction of Dermylex(TM) to the U.S. market since the day we signed our agreement, January 11, 2006. The pre-launch program and the introduction of Dermylex(TM) to dermatologists during the AAD conference will increase product awareness and will probably open new opportunities for Advitech." Mr. Beauchesne added: "With this pre-launch and the introduction of Dermylex(TM) at the AAD conference by PhotoMedex, our plan for the U.S. market is rolling out as scheduled."PhotoMedex markets its XTRAC(laser directly to physicians through its sales organization for the treatment of psoriasis. Physicians also use PhotoMedex skincare products to improve healing, following aesthetic procedures such as laser resurfacing, laser hair removal Epilation performed by laser was performed experimentally for about 20 years before it became commercially available in the mid 1990s. Intense Pulsed Light (IPL) epilators, though technically not a laser, use xenon flash lamps that emit full spectrum light. and microdermabrasion Microdermabrasion (often referred to as Microderm) is a cosmetic procedure popular in day spas, doctors' practices, and medical spas, in which the stratum corneum (dead outermost surface of the skin) is partially or completely removed by light abrasion. , and for daily use to promote healthy skin and reduce hyperpigmentation Hyperpigmentation Definition Hyperpigmentation is the increase in the natural color of the skin. Description Melanin, a brown pigment manufactured by certain cells in the skin called melanocytes, is responsible for skin color. , fine lines and wrinkles. PhotoMedex recently acquired ProCyte Corporation, a company that develops and markets therapeutic and daily use skincare and procedure-based products to dermatologists. About PhotoMedex PhotoMedex is a leader in the development, manufacturing and marketing of medical laser products and services. In addition, as a result of the merger with ProCyte, PhotoMedex now develops and markets products based on its patented, clinically proven Copper Peptide technology for skin health, hair care and wound care. The Company sells directly to dermatologists, plastic and cosmetic surgeons, spas and salons and through licenses with strategic partners in the consumer market, including a long-term worldwide license agreement with Neutrogena(R), a Johnson & Johnson company. ProCyte brands include Neova(R), Ti-Silc(R), VitalCopper(R), Simple Solutions(R) and AquaSante(R). About Dermylex(TM) Dermylex(TM) is Advitech's orally administered product for mild to moderate plaque psoriasis. Dermylex(TM) is based on Advitech's XP-828L, a bioactive ingredient with proven clinical efficacy.On July 5th, 2005, the Company reported positive results from its Phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II of XP-828L for treating mild to moderate psoriasis patients. The 112-day, multi-center, double blind, placebo-controlled study, involving 84 patients, confirmed the efficacy and excellent safety profile of XP-828L for treating mild to moderate psoriasis. About Advitech Advitech is a biotechnology company specializing in the development of clinically tested bioactive ingredients for chronic immune-mediated inflammatory diseases (IMID IMID Immunomodulatory Drug (Celgene) IMID Immune Mediated Inflammatory Disorders ), such as psoriasis and inflammatory bowel diseases. Advitech's common shares are listed on the TSX Venture Exchange TSX Venture Exchange Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors. under the symbol AVI. The number of common shares outstanding is 54,799,818. This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward- looking statements. The TSX Venture Exchange does not accept responsibility for the ad equacy or accuracy of this release. ADVITECH INC. (TSX VENTURE:AVI) |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion